StageZero Life Sciences ('StageZero' or the 'Company') (TSX: SZLS) (OTCQB: SZLSF), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its third quarter financial results for the three months and nine months ended September 30, 2022, and provided an update on its business progress.

Operational Updates and Recent Highlights

During Q3 2022 we: Continued the transition from COVID to cancer testing, diagnosis and treatment, with COVID contributing marginal revenue during the Quarter.

Focused strongly on large employers, insurers and re-insurers, and clinics and healthcare systems with respect to early cancer screening, leveraging our previous COVID contacts.

Initiated early cancer screening programs with large employers and are reporting results, with follow up.

Are collaborating with the Health and Safety Committees of multiple Fire Fighter stations, across many jurisdictions in Ontario, to incorporate multi-year cancer screening programs in their budgets. Testing begins with budget approval. (there are 11,000 full time and 19,000 volunteer Fire Fighters in Ontario).

Individual, independent, Fire Fighter screening has commenced.

Initiated discussions with Fire Fighters in other Provinces in Canada and multiple States in the US.

Expanding CareOncology programs to clinic and healthcare groups for referral. Data publication a key endpoint.

Expansion into the 750 million population EU a key focus

About StageZero Life Sciences, Ltd.

StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT).

The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.

AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.

Aristotle, as well as additional cancer diagnostics (ColonSentry, BreastSentry, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).

StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as 'expects', 'will' and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Contact:

Rebecca Greco

Tel: 1-855-420-7140

Email: rgreco@stagezerols.com

(C) 2022 Electronic News Publishing, source ENP Newswire